Union Health Ministry on Tuesday said that the expert committee on vaccine administration, chaired by NITI Aayog's Dr VK Paul, will meet on Wednesday to consider "logistics and ethical aspects" of procurement and administration of vaccines against the coronavirus disease.
"The committee will also consider other issues related to logistics of the vaccine like cold chain, inventory, how to arrange resources to procure vaccine and how to address the equity issues linked to vaccination", Bhushan added.
The committee on vaccine administration will engage with all the stakeholders including state governments and vaccine manufacturers, the ministry said in a tweet. ICMR scientist Professor Balaram Bhargava said- We now have three corona vaccines, which are in different stages of clinical trials. He was responding to a question on whether India plans to tie up with Russian Federation for procuring the vaccine which Moscow claims to have developed.
"We look forward to sharing initial clinical data from this Phase 1/2 study in Q4, which we expect to enable dose selection for late phase clinical trials". "The two vaccines - Bharat Biotech vaccine and DNA vaccine of Zydus Cadila have completed phase 1 and will begin phase 2 while third is Oxford vaccine", said top ICMR scientist Professor Balram Bhargava.
Pune-based Serum Institute of India has already tied up for the mass production of Oxford-Astrazeneca's vaccine candidate, along with monetary investments made by Bill and Melinda Gates Foundation for the vaccine distribution of over 100 million dosages in over 90 middle-income countries. The Serum Institute has said it has entered into a new partnership with worldwide vaccine alliance Gavi and Bill & Melinda Gates Foundation to accelerate manufacturing and delivery of up to 100 million doses of vaccines for India and other low and middle-income countries.